In the present study, we evaluated the efficacy of sildenafil and pentoxifylline combined therapy in the treatment of vasculogenic erectile dysfunction.
Sixty-eight patients with various degrees and types of vasculogenic erectile dysfunction were included in the study. The patients were recommended to take oral sildenafil (minimum two 50-mg tablets/week) 1 h prior to sexual intercourse for 4 weeks. After 4 weeks of washout period, patients were recommended to take combined therapy (minimum two 50-mg tablets/week sildenafil 1 h prior to sexual intercourse and 1.2 g of pentoxifylline/day divided into three doses) for an additional 4-week period. Both treatment regimes were evaluated with the international index of erectile function (IIEF).
Mean IIEF score was higher after sildenafil treatment when compared to pre-treatment score (14.2 ± 4.3 and 8.6 ± 4.2, respectively, P < 0.05). Likewise after the combination treatment, mean IIEF score was higher when compared to pre-treatment score (18.1 ± 5.2 and 8.6 ± 3.8, respectively, P < 0.05). The increase in the IIEF score was 5.62 ± 2.08 in the sildenafil only group whereas increase in the IIEF score was 9.51 ± 3.77 in the combination therapy group. There was a statistically significant increase in the combination group when compared to the sildenafil only group (P < 0.001).
Our study suggests that use of sildenafil citrate and pentoxifylline combined therapy could be effective in the management of patients with vasculogenic erectile dysfunction.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Lizza EF, Rosen RC (1999) Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res 11:141–143
Sattar AA, Wery D, Golzarian J et al (1996) Correlation of nocturnal penile tumescence monitoring duplex ultrasonography and infusion cavernosometry for the diagnosis of erectile dysfunction. J Urol 155:1274–1276
Oates CP, Pickard RS, Powell PH et al (1995) The use of duplex ultrasound in the assessment of arterial supply to the penis in vasculogenic impotence. J Urol 153:354–357
Padma-Nathan H, Giuliano F (2001) Oral drug therapy for erectile dysfunction. Urol Clin North Am 28:321–334
Ralph D, McNicholas T (2000) UK management guidelines for erectile dysfunction. BMJ 321:499–503
Ward A, Clissold SP (1987). Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50–97
Korenman SG, Viosca SP (1993) Treatment of vasculogenic sexual dysfunction with pentoxifylline. J Am Geriatr Soc 41:363–366
Peskircioglu L, Karabulut A, Deniz E et al (1996) The role of pentoxifylline in the treatment of erectile dysfunction due to borderline arterial insufficiency. Br J Urol 77:563–565
Boolell M, Gepi-Attee S, Gingell JC et al (1996) Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257–261
Rosen RC, Riley A, Wagner G et al (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830
Rajfer J (1994) Andrology. J Urol 152:891
Feldman HA, Goldstein I, Hatzichristou DG et al (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 151:54–61
Rahman MA (1999) Pathophysiology of erectile dysfunction. In: Vaughan ED Jr, Perlmutter AP (eds) Atlas of clinical urology, Vol 1. Current Medicine, Philadelphia, PA, pp 1–6
Baum N, Rhodes D (1995) A practical approach to the evaluation and treatment of erectile dysfunction. A private practitioner’s viewpoint. Urol Clin North Am 22:865–877
Jarow JP, Nana-Sinkam P, Sabbagh M et al (1996) Outcome analysis of goal directed therapy for impotence. J Urol 155:1609–1612
Hanash KA (1997) Comparative results of goal oriented therapy for erectile dysfunction. J Urol 157:2135–2138
Boolell M, Allen MJ, Ballard SA, et al (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47–52
Fabbri A, Aversa A, Isidori A (1999) Sildenafil and erectile dysfunction. J Endocrinol Invest 22:486–492
Knoll LD, Benson RC Jr, Bilhartz DL, et al (1996) A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence. J Urol 155:144–146
About this article
Cite this article
Ozdal, O.L., Ozden, C., Gokkaya, S. et al. The effect of sildenafil citrate and pentoxifylline combined treatment in the management of erectile dysfunction. Int Urol Nephrol 40, 133–136 (2008). https://doi.org/10.1007/s11255-007-9255-1